Sponsor

Celcuity Inc

Clinical research sponsor

Published trials9

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

9 shown

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 · lead sponsor · 2025-07-24

RECRUITING

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899 · lead sponsor · 2024-01-01

RECRUITING

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · lead sponsor · 2022-12-08

ACTIVE_NOT_RECRUITING

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerNCT02684032 · lead sponsor · 2016-06-14

COMPLETED

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009NCT05134922 · lead sponsor

AVAILABLE

Fulvestrant + Neratinib In Breast CancerNCT04901299 · collaborator · 2023-07-01

WITHDRAWN

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestNCT05243641 · collaborator · 2022-08-18

TERMINATED

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastNCT03812393 · collaborator · 2019-06-21

UNKNOWN

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersNCT03911973 · collaborator · 2019-04-17

ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor5

collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.